Rheumatology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Ann Rheum Dis. 2018 Sep;77(9):1333-1338. doi: 10.1136/annrheumdis-2018-213452. Epub 2018 May 14.
Renal transplantation is the optimal treatment for selected patients with end-stage renal disease (ESRD). However, the survival benefit of renal transplantation among patients with ESRD attributed to granulomatosis with polyangiitis (GPA) is unknown.
We identified patients from the United States Renal Data System with ESRD due to GPA (ESRD-GPA) between 1995 and 2014. We restricted our analysis to waitlisted subjects to evaluate the impact of transplantation on mortality. We followed patients until death or the end of follow-up. We compared the relative risk (RR) of all-cause and cause-specific mortality in patients who received a transplant versus non-transplanted patients using a pooled logistic regression model with transplantation as a time-varying exposure.
During the study period, 1525 patients were waitlisted and 946 received a renal transplant. Receiving a renal transplant was associated with a 70% reduction in the risk of all-cause mortality in multivariable-adjusted analyses (RR=0.30, 95% CI 0.25 to 0.37), largely attributed to a 90% reduction in the risk of death due to cardiovascular disease (CVD) (RR=0.10, 95% 0.06-0.16).
Renal transplantation is associated with a significant decrease in all-cause mortality among patients with ESRD attributed to GPA, largely due to a decrease in the risk of death to CVD. Prompt referral for transplantation is critical to optimise outcomes for this patient population.
肾移植是治疗特定终末期肾病(ESRD)患者的最佳方法。然而,对于患有肉芽肿性多血管炎(GPA)导致的 ESRD 患者,肾移植的生存获益尚不清楚。
我们从 1995 年至 2014 年间的美国肾脏数据系统中确定了患有 GPA 导致的 ESRD(ESRD-GPA)的患者。我们将分析仅限于等待移植的患者,以评估移植对死亡率的影响。我们对患者进行随访,直至死亡或随访结束。我们使用汇总逻辑回归模型,将移植作为时变暴露,比较接受移植和未接受移植的患者的全因死亡率和病因特异性死亡率的相对风险(RR)。
在研究期间,有 1525 名患者等待移植,其中 946 名患者接受了肾移植。多变量调整分析显示,接受肾移植与全因死亡率降低 70%相关(RR=0.30,95%CI 0.25 至 0.37),这主要归因于心血管疾病(CVD)死亡率降低 90%(RR=0.10,95%CI 0.06 至 0.16)。
肾移植与 GPA 导致的 ESRD 患者的全因死亡率显著降低相关,这主要归因于 CVD 死亡率的降低。对于这一患者群体,及时转诊进行移植对于优化治疗结果至关重要。